Head-to-head comparison of pembrolizumab-axitinib versus pembrolizumab-lenvatinib in metastatic RCC: Real world data from the Canadian Kidney Cancer Information System (CKCis) database.
Alexandre da Silva Faco(McGill University Health Centre), Ramy Saleh(McGill University Health Centre), Aly‐Khan A. Lalani(Juravinski Cancer Centre), Mohammad Hassan Hodroj(McGill University Health Centre), Mohammad Amin Salehi(McGill University Health Centre), Georg A. Bjarnason(Sunnybrook Health Science Centre), Jacob Taylor(The University of Texas Southwestern Medical Center), Vincent Castonguay(Centre hospitalier universitaire de Québec), Feras A. Moria(McGill University Health Centre), Daniel Yick Chin Heng(University of Calgary), Rodney Breau(Ottawa Hospital), Naveen S. Basappa(University of Alberta), Sunita Ghosh(University of Alberta), Dominick Bosse(University of Ottawa), Jeffrey Graham(CancerCare Manitoba), Christian K. Kollmannsberger(BC Cancer Agency), E Winquist(Western University), Antonio Finelli(University of Toronto), Simon Tanguay(McGill University Health Centre)
Cited by 0
Related Papers
Change in neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
|Journal for ImmunoTherapy of Cancer|2018|267
Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC).
|Journal of Clinical Oncology|2014|233
Metabolomic adaptations and correlates of survival to immune checkpoint blockade
|Nature Communications|2019|225